November 22nd 2024
A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.
November 21st 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
MRTX849 Shows Safety, Tolerability in Treating KRAS G12C
November 29th 2019In patients whose solid<strong> </strong>tumors harbor a mutation in <em>KRAS </em>G12C, therapy with MRTX849 has produced promising responses and acceptable toxicity across 3 tumors types, according to data presented at the 2019 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.
Read More
Later-Line Management of Metastatic Triple Negative Breast Cancer
November 27th 2019Triple-negative breast cancer — defined as tumors that lack expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 amplification— is a heterogenous disease and clinically represents a major unmet need in the field of oncology. TNBC is associated with aggressive tumor biology and higher risk of recurrence and visceral metastasis, including brain metastasis.
Read More
O'Shaughnessy Discusses Emerging Data That Could Affect TNBC Treatment Options
November 20th 2019Joyce A. O’Shaughnessy, MD, led a group of physicians at a recent Targeted Oncology live case-based peer perspective event in discussion on emerging data that could affect treatment options for patients with triple-negative breast cancer in the future.
Read More
A Look Back at FDA News from October 2019
November 1st 2019In October 2019, the FDA approved a new treatment option for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer, as well as a new dosing regimen for patients receiving moderately emetogenic chemotherapy. Additionally, the FDA granted breakthrough therapy designations to 2 therapies, as well as an orphan drug designation, a priority review, and 2 fast track designations.
Read More
KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer
November 1st 2019Hope S. Rugo, MD, discusses the potential role of immunotherapy for the treatment of patients with triple-negative breast cancer (TNBC), based on data from the KEYNOTE-522 clinical trial. Immunotherapy has been very exciting in this setting.
Watch
PARP Inhibitors, Early-Stage Treatment Signal Shift in Focus for Patients With TNBC
October 31st 2019An expanded treatment array that uses PARP inhibitors, antibody–drug conjugates, and inhibitors of the AKT and MEK pathways gives patients with triple-negative breast cancer reason for hope.
Read More
Evolving Guidelines Reclassify Less Common HER2 Result Patterns
October 30th 2019Updated breast cancer guidelines have led to clearer diagnosis and management protocols in the past 2 decades, making them a necessary tool to help oncologists stay current in the face of a rapidly evolving knowledge base. To address less common HER2 result patterns, updated guidelines are reclassifying these cases to either HER2-negative or -positive groupings.
Read More
Expert Highlights Precision Medicine in Breast Cancer During Breast Cancer Awareness Month
October 28th 2019In an interview with Targeted Oncology, Hannah Linden, MD, discussed the current treatment landscape during Breast Cancer Awareness Month. She also highlighted the value of liquid biopsy, tissue biopsy, and imaging techniques in this space for identifying patients with targetable mutations and how these assays and techniques can further impact treatment and outcomes of these patients.
Read More
FDA Considers New Warning and Label Recommendations for Breast Implants
October 28th 2019According to a statement from the FDA, the agency has issued a draft guidance proposing labeling recommendations for breast implant manufacturers that would help patients understand the benefits and risks of implants. The labeling recommendations would include the addition of a boxed warning.
Read More
Updated BLA Submitted to FDA for Eflapegrastim as Chemotherapy-Induced Neutropenia Treatment
October 25th 2019An updated Biologics License Application has been submitted to the FDA for eflapegrastim for the treatment of neutropenia in patients with cancer receiving myelosuppression drugs, according to a press release from Spectrum Pharmaceuticals.
Read More
Expert Discusses the Selection of Individuals for Germline Testing Based on Breast Cancer Risk
October 25th 2019In an interview with <em>Targeted Oncology</em>, at the Lynn Sage Breast Cancer Symposium, Susan Domchek, MD, explained the meaning of low to moderate penetrance genes and how they are indicative of breast cancer risk. She also explained the importance of germline and genetic testing to reveal mutations in these genes.
Read More
Margetuximab Demonstrates Modest OS Benefit in HER2+ Metastatic Breast Cancer
October 24th 2019Margetuximab, an investigational monoclonal antibody, prolonged survival in pretreated patients with HER2-positive metastatic breast cancer when combined with chemotherapy, according to the second interim analysis of the phase III SOPHIA trial, which was reported in a press release from MacroGenics.<br />
Read More
FDA Approves New Aprepitant Dosing Regimen for CINV After MEC
October 23rd 2019The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />
Read More
Tucatinib Triplet Reduces Risk of Death in Metastatic HER2+ Breast Cancer
October 21st 2019In the HER2CLIMB trial, the addition of tucatinib to trastuzumab and capecitabine significantly improved progression-free survival in patients with locally advanced, unresectable, or metastatic HER2-positive breast cancer, meeting the primary endpoint of the study, according to a press release from Seattle Genetics.<br />
Read More
Abemaciclib Triplet Prolongs PFS in HR+/HER2+ Breast Cancer
October 18th 2019The triplet combination of abemaciclib, trastuzumab, and fulvestrant showed a significant statistical improvement in progression-free survival compared with chemotherapy and trastuzumab in patients with heavily pretreated, hormone receptor–positive, HER2-positive breast cancer, according to the results of the phase II monarcHER trial.
Read More
FDA Grants Priority Review of DS-8201 for HER2+ Metastatic Breast Cancer
October 17th 2019The FDA has accepted and granted a priority review to a biologics license application for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of patients with HER2-positive metastatic breast cancer.
Read More
Phase III Trial Explores Combination of Tucatinib and T-DM1 in HER2+ Breast Cancer
October 11th 2019A phase III trial, HER2CLIMB-02, has been initiated to investigate the combination of tucatinib and ado-trastuzumab emtansine in patients with locally advanced or metastatic HER2-positive breast cancer. The results of the trial will support registration for tucatinib in the United States.
Read More
Broader Applications for Targeted Agents in Breast Cancer Expand Patient Use
October 8th 2019A greater understanding of the mechanisms underlying endocrine resistance, along with the development of targeted agents directed at key regulatory oncogenic pathways, continue to lead to new options in the treatment of hormone receptor–positive, HER2-negative breast cancer. These therapies offer the promise of better disease control rates and improved quality of life for patients with advanced disease.
Read More
Experts in Oncology Highlight Key Abstracts Presented at the 2019 ESMO Congress
October 7th 2019Following the 2019 ESMO Congress, experts across various fields highlighted some next steps and how these treatment options will improve the treatment landscape for patients with ovarian, lung, breast, GI, or GU cancers. Overall, the abstracts presented at this year’s meeting will change the treatment paradigm in a number of patient populations.
Read More
Annual Meeting Continues Moving Personalized Medicine to the Fore
October 7th 2019The introduction of<strong> </strong>CDK4/6 inhibitors for the treatment of hormone receptor–positive, HER2-negative breast cancer has transformed therapy management and extended survival for this patient population. The next step in the process of tailoring therapy towards individual patients is the introduction of targeted therapies for patient subsets with driver aberrations.
Read More
ASCO Adds Oral Anticoagulants to Venous Thromboembolism Guidelines for Patients With Cancer
October 4th 2019The addition of direct oral oral anticoagulants for the management of venous thromboembolism in patients with cancer is the latest change to previous guidelines issued by the American Society of Clinical Oncology.
Read More
Patient With a PIK3CA-Positive Tumors Exhibits Hyperglycemia Associated With Alpelisib
October 3rd 2019The approval of alpelisib in May 2019 poses a challenge to oncologists and their practices with the emergence of hyperglycemia as an AE associated with PI3K inhibitors. Managing the patient effectively requires a multidisciplinary team approach that involves counseling up front, monitoring throughout the course of therapy, and input and feedback from the team of oncologists, advanced practice providers, pharmacists, and dietitians.
Read More
Clinically Meaningful Improvement in TRK Fusion Cancer Detected with Larotrectinib
October 3rd 2019Using a measure known as the growth modulation index, patients with TRK fusion–positive cancers who were treated with larotrectinib had a clinically meaningful improvement in progression-free survival compared with the time to progression on their prior treatment, an analysis of patients enrolled in 1 of 3 clinical trials has found.
Read More
FDA Approves Labeling Supplement on Prophylaxis for Neratinib in HER2+ Breast Cancer
October 3rd 2019The FDA has approved a labeling supplement for neratinib for the extended adjuvant treatment of patients with HER2-positive early-stage breast cancer. The labeling supplement adds safety information based on interim findings from the phase II CONTROL trial, which investigated the use of preventive strategies to reduce the incidence and severity of neratinib-associated diarrhea.
Read More